

## Transforming Food Allergy Treatment Via a Novel Immunotherapy Platform

### Our first application targets the >\$7 billion U.S. peanut allergy market

#### Problem

**Food allergy market is in dire need of new solutions**

- **Large, growing market:** >220 million people globally with food allergies; 33 million in U.S.
- **Suboptimal treatment options:** Current solutions do not deliver disease modification with robust safety, efficacy, and adherence profiles
- **Significant unmet need:** Causes severe health events and lifestyle impacts, with no cure

#### Our Solution

**New therapeutic approach for treatment of peanut and other food allergies: oral mucosal immunotherapy (OMIT)**

- **Novel approach:** Created by transforming complex patented biochemistry into a novel therapeutic solution for food allergy desensitization
- **Simplified delivery:** Therapeutic agents embedded in a fully functional toothpaste that can be conveniently administered simultaneously as patients brush their teeth

#### What Makes Us Different

**Delivers dramatically reduced risk profile in a best-in-class agent that 9 in 10 subjects<sup>1</sup> will use**

- **High adherence:** Simple toothpaste delivery provides opportunity to be “maintenance product of choice” for patients started on other solutions
- **Significantly reduced risk profile:** API is expelled after brushing; reduced risk of systemic reactions and GI distress
- **Safe:** Phase 1 / 2 DBPC\* OMEGA Trial in adults met all primary and secondary safety objectives (safety, adherence, tolerability)
- **Efficacious:** OMEGA Trial exploratory objective provided indications of efficacy in difficult-to-treat adult population
- **Lower adoption barriers:** Fewer, shorter up-dosing office visits required

#### Opportunity

**Opportunity to get in early on technology with high expected ROI that targets an established, reimbursed market**

- **Multibillion \$ market:** First application targets >\$7B peanut allergy market; multiple applications and opportunities enabled by unique immunotherapy platform technology
- **Opportunity with reduced risk and high expected ROI:** Recently released clinical trial results positive and received broad media coverage; advanced product/clinical development; strong global IP portfolio
- **Minimal competition:** Only two products approved for food allergies. One has faced significant challenges due to its inconvenient administration, a challenging safety profile, and a limited indication.<sup>†</sup> The other product is approved for multiple food allergies, but is a costly<sup>‡</sup> injection dosed every 2-4 weeks and is not a disease-modifying treatment.

#### Backed by an Experienced Team

**Experience successfully bringing innovation to market, including in biotech, pharma, and allergy markets**

### Intromune Is Currently Seeking \$38 Million in Series B Funding Funding for Phase 2 pediatric study